Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 03, 2023 16:05 ET | Source: Avadel Pharmaceuticals plc

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

DUBLIN, May 03, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of...
May 01, 2023 13:20 ET | Source: Avadel Pharmaceuticals plc

Avadel Pharmaceuticals Announces Final FDA Approval of LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension as the First and Only Once-at-Bedtime Oxybate for Cataplexy or Excessive Daytime Sleepiness in Adults with Narcolepsy

- Granted Orphan Drug Exclusivity through May 1, 2030 - -Advanced commercial preparations on track; LUMRYZ product availability expected in early June - - Final approval supported by robust efficacy...
April 20, 2023 16:05 ET | Source: Avadel Pharmaceuticals plc

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

DUBLIN, Ireland, April 20, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation...
April 10, 2023 08:00 ET | Source: Avadel Pharmaceuticals plc

Avadel Pharmaceuticals to Present at the 22nd Annual Needham Healthcare Conference

DUBLIN, Ireland, April 10, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
April 03, 2023 16:05 ET | Source: Avadel Pharmaceuticals plc

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

DUBLIN, April 03, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee...
March 30, 2023 07:00 ET | Source: Avadel Pharmaceuticals plc

Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

• LUMRYZ™ NDA amendment filed March 1 requesting FDA final approval • Received FDA authorization to import LUMRYZ in advance of final approval decision; shortens timeline between potential approval...
March 29, 2023 21:27 ET | Source: Avadel Pharmaceuticals plc

Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 30

DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
March 29, 2023 21:24 ET | Source: Avadel Pharmaceuticals plc

Avadel Pharmaceuticals Announces Pricing of Public Offering of ADSs and Series B Preferred Shares

DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (“Avadel”) (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced...
March 29, 2023 16:13 ET | Source: Avadel Pharmaceuticals plc

Avadel Pharmaceuticals Announces Proposed Underwritten Public Offering of ADSs and Series B Preferred Shares

DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (“Avadel”) (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced...
March 29, 2023 16:01 ET | Source: Avadel Pharmaceuticals plc

Avadel Pharmaceuticals Enters into Royalty Agreement with RTW Investments for up to $75 Million

– In parallel, extended maturity on $96.2 million of convertible notes to April 1, 2027 – Strategic financings strengthen the company’s balance sheet in advance of potential commercialization of...